105 cells/ml in Iscove's medium supplemented with 10% FCS, 2-ME (50 AM), L-arginine (0.55 MM), L-asparagine (0.24 mM), and L-glutamine (1 .5 mM). Medium was changed every other day, and cell concentrations were maintained at 1-5 X 105 cells/ml . Factordependent plasmacytoma and hybridoma cell lines were maintained in the same medium supplemented with appropriate concentrations of T cell supernatant (usually 2% for plasmacytomas and 0.01 % for hybridomas) .
Preparation of TUC2.15 Supernatant . Helper T cell clone TUC2.15 was derived from C57BL/6 mice immunized with keyhole limpet hemocyanin (KLH) . For mass production of this clone, 5 X 106 T cells were cultured with 2 X 108 syngeneic spleen cells (irradiated with 2,000 rad from a cesium source) in 50 ml Dulbecco's modified Eagle's medium containing 25 Ag/ml KLH and supplemented with amino acids, 2-ME, and FCS as described above for plasmacytoma cells . After 10-15 d, these cultures yielded 4.0-5 .0 X 10' TUC2.15 cells . For the preparation of TUC2.15 supernatant, 10-d-old cultures were washed in medium without serum and the cells were incubated for 3-4 d with clonotypic monoclonal antibody 3D7 in medium with a low protein concentration (0.5% FCS or 10 ug/ml human transferrin). The 3D7 antibody, which was derived from 129/Sv mice immunized with TUC2 .15, stimulated lymphokine secretory activity and proliferation of TUC2.15, but of no other helper T cell clones . It was used here as a 10,000-fold diluted ascites.
Biochemical Procedures . Crude TUC2.15 supernatant was concentrated by adsorption on silicic acid (3 g/liter for 3 h at 4°C) and elution with 50% ethylene glycol and 50% 1 .4 M NaCl containing 12 mM phosphate buffer, pH 7.2. Aliquots of this material were analyzed by gel filtration, isoelectric focusing, or reversed-phase HPLC. Gel filtration was carried out on an Ultrogel AcA 54 column (LKB, Bromma, Sweden) equilibrated with 18% ethylene glycol in 1 M NaCl containing 12 mM phosphate buffer pH 7.2. For isoelectric focusing, samples were applied to a prefocused (600 V for 1 h) flat-bed polyacrylamide (5%) gel equilibrated with pH 3.5-10 ampholines (2.5%, LKB) and focused for 2 h at 1,000 V. Material eluted from the gel was tested for hybridoma and plasmacytoma growth factor activities after dialysis against culture medium . Reversed-phase HPLC was performed on a Cl-column (TSK TMS 250 ; LKB) equilibrated in 0.05% trifluoroacetic acid (TFA) and eluted at 0.8 ml/min with a gradient of acetonitrile containing 0.05% TFA . 1-min fractions were collected . Pure IL-HP1 was obtained from crude TUC2 .15 supernatant by sequential gel filtration, anion exchange, and reversed-phase HPLC as described (11) . Upon SDS-PAGE, material prepared according to this procedure is resolved in multiple bands (Fig. 1) , which all display HGF activity. The purity of this material has been further demonstrated by the finding of a single NH2-terminal amino acid sequence (11) . Semipurified BSF-1 was obtained after gel filtration, anion-exchange and Cl reversed-phase HPLC as reported (11) . This material, which was active on antiIgM-stimulated B cells, was found to be free from IL-2 and IL-HP I .
Growth Factor Assays. Hybridoma growth factor (HGF) titrations were performed by incubating mouse factor-dependent B cell hybridoma 7TD1 (2,000 cells/microwell) with serial dilutions of the fractions to be tested in a final volume of 0.2 ml. Cell numbers were evaluated after 4 d at 37°C by measuring hexosaminidase levels as described (11) . A titer of 1 U/ml was arbitrarily assigned to material that produced half-maximal growth of hybridoma 7TD 1 . The plasmacytoma growth factor assay was carried out on appropriately diluted fractions with factor-dependent plasmacytoma cell lines (3,000 cells/microwell) . Cells were incubated in triplicate cultures and pulsed with methyl-[8H]thymidine (0.5 PCi/well) during the last 12 h of a 72-h incubation . For clarity, standard errors, which did not exceed 10% of the means, are not shown. IL-2 was measured with the CTLL assay (13) .
Results and Discussion
of six plasma cell tumors that failed to grow in vitro in normal primary cultures, five readily gave rise to vigorous cell lines in the presence of medium conditioned by helper T cell clone TUC2 .15, which was previously shown to support the growth of B cell hybridomas (11) . In the absence of supernatant, not Silver-stained SDS-PAGE of purified IL-HPL Sample was run under nonreducing conditions in a 15% polyacrylamide gel as described by Laemmli (14) and stained according to Morrissey (15) . Bands at 67 and 59 kD are staining artefacts. 
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11 line could be established in this experiment. By extrapol growth curves (shown in Fig. 2 for MOPC 104E and TEPC 1033) to time 0, the frequency of cells capable of proliferation in primary cultures supplemented with supernatant could be evaluated for four of the five successfully adapted tumors (Table 1) . These frequency estimates, which ranged from 0.03 to 0.5, were at least five orders of magnitude above those of cultures set up in the absence of T cell supernatant.
several months in culture, four of the five plasmacytoma cell lines remained strictly dependent on the continuous presence of TUC2 .15 supernatant in the culture medium. The exception was the MOPC 315 line, which was able to proliferate, although at a reduced rate, in the absence of supernatant. The four lines that failed to survive without supernatant were used in subsequent attempts to identify T cell-derived plasmacytoma growth factors. Screening of a panel of murine helper T cell supernatants showed a strong correlation between hybridoma and plasmacytoma growth factor titers (n = 12, r = 0.97 for MOPC 173), suggesting that the same factor could be responsible for both hybridoma and plasmacytoma growth . This idea was further supported by the finding that both activities copurified in analytical fractionations of TUC2 .15 supernatant. As illustrated in Fig. 3 for MOPC 173, it was impossible to separate plasmacytoma growth factor from hybridoma growth factor by either gel filtration, isoelectric focusing, or reversed-phase HPLC. Identical results were obtained with MOPC 104E, RPC 20, and TEPC 1033. The heterogeneity of the plasmacytoma and hybridoma growth factor activities in isoelectric focusing was most probably due to variations in glycosylation because it was considerably reduced upon treatment with neuraminidase (results not shown) . Collectively, these observations provided strong evidence for the idea that the hybridoma growth factor previously identified as IL-HP I (11) represented the major and probably the only plasmacytoma growth factor present in TUC2 .15 supernatant . Further proof of this hypothesis was obtained with IL-HPI purified to homogeneity, which, at optimal concentration, induced maximal plasmacytoma proliferations that were comparable with those induced by crude TUC2 .15 supernatant. From the dose-response curves shown in Fig. 4 , the concentrations of IL-HPI required for half-maximal growth of plasmacytomas were evaluated at approximately 30 pM . Noteworthy, two IL-HP I-dependent hybridomas, which we have used as indicator cells in the IL-HP 1 assay, required 200-fold less growth factor for half-maximal proliferation than the plasmacytoma lines. Although the significance of this difference is presently not clear, it is conceivable that some complementation occurs in hybridomas, resulting in an abnormally high sensitivity to IL-HP I . The fact that IL-HP I-independent cells emerge much more frequently from IL-HPI-dependent hybridoma lines than from plasmacytoma lines (our unpublished observation) seems to support this view . i.p. injection of 5 X 10 5 cells, the three lines were found to form tumors that killed the animals in less than 2 wk, indicating that IL-HP1-dependent plasmacytomas are still able to proliferate in vivo . Whether this means that these cells do not need IL-HP1 in vivo or that there is enough IL-HP1 or related molecules in the peritoneal cavity of pristane-treated mice is not known .
Another problem that remains to be solved is that of the specificity of IL-HP 1 for cells of the B cell lineage. The importance of this question is highlighted by the recent finding that BSF-1, a lymphokine formerly thought of as a B cellspecific factor, has now been found to stimulate the proliferation of certain T cell lines (16, 17) . As a first step in the analysis of the specificity of IL-HP1, we therefore compared the effects of IL-2, BSF-1, and IL-HP1 on the proliferation of IL-2-dependent cytolytic T cell line (CTLL), helper T cell clone TUC2 .15, and plasmacytoma TEPC1033 . As shown in Table 11 , TUC2 .15 cells, which responded very well to BSF-1 and to IL-2, failed to proliferate in the presence of IL-HP1 even at a concentration in 100-fold excess of that required by plasmacytomas. Similar results were obtained with several other helper T cell clones . Although these results do not prove that IL-HP1 is a B cell-specific growth factor, they clearly show that this molecule does not stimulate the growth of every established cell line. Moreover, the data in Table II also formally demonstrate the functional difference between BSF-1 and IL-HP1, which corroborates the physicochemical differences already noted between these molecules (11, 18, 19) .
Many different cell types, including macrophages (3, 9, 20) , endothelial cells (21) , peripheral blood cells (22) , fibroblasts, (23) and T lymphocytes (11 and this report), have now been reported to secrete growth factors for hybridomas and plasmacytomas. It is difficult for the time being to evaluate the structural relations between these factors because, in most cases, they have not been cloned or purified to homogeneity. This situation is complicated even further by the fact that the structural data that are available are related to factors derived from different species. This is the reason why we do not presently know whether IL-HP 1 is the mouse homologue of the plasmacytoma growth factor that we recently identified in media conditioned by human fibroblasts, and which appeared to be identical with a molecule previously described as 26K factor, also known as interferon a2 (Van Damme, J., G. Opdenakker, A. Billiau, M . Rubina, R. Simpson, S. Cayphas, A . Vink, and J. Van Snick, manuscript submitted for publication. Summary We have recently described the purification and NH2-terminal amino acid sequence of a T cell-derived hybridoma growth factor that was provisionally designated interleukin-HPI (IL-HPI). Here we report that a T cell supernatant containing high titers of this hybridoma growth factor considerably facilitated the establishment of primary cultures of murine plasmacytomas . Most plasmacytoma cell lines derived from such cultures remained permanently dependent on IL-HPI-containing T cell supernatant for both survival and growth in vitro. These cell lines, however, retained their ability to form tumors in irradiated pristane-treated mice .
Analytical fractionation of a T cell supernatant rich in IL-HPI by either gel filtration, isoelectric focusing, or reversed-phase HPLC revealed the existence of only one plasmacytoma growth factor activity that strictly copurified with IL-HP 1, strongly suggesting the identity of both factors . This conclusion was further supported by the finding that IL-HPI purified to homogeneity supported the growth of both B cell hybridomas and plasmacytomas. For half-maximal growth, plasmacytomas, however, required a concentration of IL-HP1 of^"30 pM, which is^200 times higher than that required by B cell hybridomas . A clear difference in the specificity of IL-HP1 and B cell stimulatory factor 1 (BSF-1) was demonstrated by the finding that IL-HP 1-dependent plasmacytomas did not survive in the presence of BSF-1, whereas helper T cell lines that proliferated in the presence of BSF-1 failed to respond to IL-HP1 .
